October 2023 in “Benha Journal of Applied Sciences” Methotrexate and vitamin D3 are potentially more effective and safer than triamcinolone for treating localized alopecia areata.
5 citations
,
January 2024 in “Journal of the American Academy of Dermatology” Use benzoyl peroxide, retinoids, antibiotics, and isotretinoin for acne, and combine treatments for better results.
December 2023 in “Acta dermato-venereologica” Tofacitinib is effective for treating alopecia areata, and starting treatment early may improve results.
3 citations
,
August 2020 in “Case Reports in Dermatology” Tofacitinib treatment significantly improved a patient's psoriasis, psoriatic arthritis, and alopecia universalis.
24 citations
,
October 2018 in “JAAD Case Reports” A woman's eyelash regrowth was successful using tofacitinib solution for alopecia areata.
Isotretinoin may cause temporary, reversible facial hair growth in some women.
March 2025 in “European Journal of Medical Genetics” Tofacitinib helped improve symptoms and hair growth in a patient with Aicardi-Goutières syndrome.
16 citations
,
July 2017 in “Rheumatology and Therapy” Tofacitinib, a medication for arthritis, showed potential for treating severe hair loss in a small Brazilian case series, but more research is needed.
1 citations
,
October 2023 in “Clinical, cosmetic and investigational dermatology” Tofacitinib improved hair loss and skin symptoms in a patient after secukinumab caused hair loss.
April 2016 in “Journal of the American Academy of Dermatology” Tofacitinib helped a person with total body hair loss grow hair again without bad side effects.
51 citations
,
June 2016 in “Journal of the European Academy of Dermatology and Venereology” Tofacitinib was effective in treating hair loss in two patients with alopecia universalis.
13 citations
,
November 2021 in “Pediatric Dermatology” Tofacitinib taken by mouth helps treat hair loss in children.
Oral tofacitinib effectively treats alopecia areata long-term with manageable side effects.
16 citations
,
June 2018 in “JAAD case reports” A JAK inhibitor improved both severe hair loss and chronic skin disease in one patient.
March 2020 in “Section 5: Patient safety and quality assurance” Tofacitinib and baricitinib had an acceptable level of side effects in rheumatoid arthritis patients.
227 citations
,
April 2023 in “The Lancet” Ritlecitinib effectively treats alopecia areata and is well-tolerated.
June 2026 in “Dermatology and Therapy” Ritlecitinib provides new treatment options for diverse alopecia areata patients.
research ACNE
58 citations
,
January 1997 in “Dermatologic Clinics” Acne significantly affects mental health and quality of life, with research suggesting hormonal and genetic factors in its development and emphasizing early treatment to prevent scarring.
May 2026 in “Zenodo (CERN European Organization for Nuclear Research)” The serum with microneedling effectively treats alopecia areata by enhancing drug delivery and is safe and patient-friendly.
March 2024 in “Clinical, cosmetic and investigational dermatology” Upadacitinib may effectively treat alopecia areata without side effects.
79 citations
,
September 2018 in “Dermatologic therapy” Oral tofacitinib can significantly improve recalcitrant lichen planopilaris.
9 citations
,
October 2021 in “International Journal of Dermatology” Tofacitinib is effective and safe for treating severe hair loss in a Saudi population.
July 2024 in “The Egyptian Journal of Hospital Medicine” 34% of patients on hepatitis C treatment had reversible skin issues.
78 citations
,
February 2011 in “Canadian Medical Association Journal” Acne treatment varies, with topical and systemic therapies effective, and more research needed on treatment order and long-term effects.
Deucravacitinib improves symptoms and reduces inflammation in Lichen Planopilaris.
March 2023 in “PARIPEX INDIAN JOURNAL OF RESEARCH” Tofacitinib helped regrow hair in most patients with severe hair loss.
August 2010 in “The Journal of Dermatology” The document concludes that low-dose acne treatment is most suitable for moderate acne, with high patient satisfaction and low relapse rates.
May 2025 in “Medical Journal of Dr D Y Patil Vidyapeeth” Low-dose isotretinoin and erythromycin effectively treated hair loss in two young sisters.
September 2024 in “Journal of the American Academy of Dermatology” Baricitinib 4 mg is effective and safe for treating severe alopecia areata.
1 citations
,
April 2015 in “The FASEB journal” UVB exposure increases skin proteins for retinoic acid synthesis and shifts their location, possibly affecting skin repair.